Takeda Oncology

Takeda Oncology is a biopharmaceutical company that specializes in the research, development, and commercialization of innovative therapies for the treatment of cancer. The company is a division of Takeda Pharmaceutical Company, a multinational pharmaceutical company based in Japan.

History

Takeda Oncology was originally established as Millennium Pharmaceuticals in 1993. In 2008, it was acquired by Takeda Pharmaceutical Company and renamed Takeda Oncology in 2013. The company has been at the forefront of cancer research, with a focus on developing novel therapies that can improve the lives of patients.

Research and Development

Takeda Oncology's research and development efforts are focused on four therapeutic areas: oncology, gastroenterology, neuroscience, and rare diseases. The company's oncology portfolio includes a range of therapies for various types of cancer, including leukemia, lymphoma, and multiple myeloma.

Products

Some of the notable products developed by Takeda Oncology include:

• Velcade (bortezomib) - A proteasome inhibitor used for the treatment of multiple myeloma and mantle cell lymphoma.
• Ninlaro (ixazomib) - An oral proteasome inhibitor used for the treatment of multiple myeloma.
• Alunbrig (brigatinib) - A kinase inhibitor used for the treatment of anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC).

Partnerships and Collaborations

Takeda Oncology has established numerous partnerships and collaborations with other biopharmaceutical companies, academic institutions, and research organizations to accelerate the development of innovative cancer therapies. These collaborations have resulted in the development of several promising drug candidates that are currently in various stages of clinical development.

See Also

• Takeda Pharmaceutical Company
• Oncology
• Pharmaceutical industry in Japan

This article is a stub related to pharmacology. You can help WikiMD by expanding it!